**SYNTHETIC BIOLOGY**

**Accelerated evolution of a minimal 63–amino acid dual transcription factor**

Andreas K. Brödel¹, Rui Rodrigues², Alfonso Jaramillo²,³,⁴, Mark Isalan¹*  

Transcription factors control gene expression in all life. This raises the question of what is the smallest protein that can support such activity. In nature, Cro from bacteriophage λ is one of the smallest known repressors (66 amino acids), and activators are typically much larger (e.g., λ cl, 237 amino acids). Previous efforts to engineer a minimal activator from λ Cro resulted in no activity in vivo in cells. In this study, we show that directed evolution results in a new Cro activator-repressor that functions as efficiently as λ cl in vivo. To achieve this, we develop phagemid-assisted continuous evolution (PACEmid). We find that a peptide as small as 63 amino acids functions efficiently as an activator and/or repressor. To our knowledge, this is the smallest protein activator that enables polymerase recruitment, highlighting the capacity of transcription factors to evolve from very short peptide sequences.

**INTRODUCTION**

DNA binding proteins that regulate transcription initiation and control gene expression are called transcription factors (TFs). The question of, “What is the smallest peptide that can function as a TF?” is a fundamental one, with broad implications for the evolution of gene regulation (1–3). However, the potential for a peptide to be a minimal TF depends on its function: whether it is an activator, a repressor, or has dual activity (table S1).

In bacteria, TFs usually recruit or block RNA polymerase to activate or repress genes of interest, respectively. Generally, repression is more straightforward to achieve because it only requires a DNA binding protein to occlude key motifs in a promoter or to block transcription elongation by “roadblock” (4). By contrast, activator TFs have to strike a balance between DNA binding, RNA polymerase recruitment, and RNA polymerase release to initiate transcription efficiently (5). Consequently, activators and dual TFs might need to be larger and more complex than repressors (table S1). These include well-studied examples such as λ cl (237 amino acids) from bacteriophage λ’s genetic switch (fig. S1A) (6).

In this study, we set out to test the minimal size limits for TFs, and in particular whether activators or dual TFs could be made as small as the smallest known repressors. Viruses have some of the smallest functional TFs, and phage λ Cro protein is one of the smallest TF repressors characterized to date, containing only 66 amino acids (7, 8). Cro controls the viral life cycle along with λ cl, and together, they function naturally as a toggle switch (fig. S1B) (6). Other examples of very small repressors are Cro from Enterobacteria phage P22 (61 amino acids) (9) and CopG (45 amino acids) (10).

It has been previously shown that Cro might potentially be converted into an activator by transfecting the activating surface patch of λ cl onto the surface of Cro (11). This can be done as molecular models of λ cl and Cro suggest that α helices two and three of each protein lie in nearly identical positions. As a result, α helices of both TFs are positioned to interact with the same part of RNA polymerase, and Cro might become an activator if α helix two were suitably engineered. However, a rationally engineered Cro variant had only a trace of detectable activity in vitro and none in vivo, in Escherichia coli, because of its low affinity for λ operators (11). Cro is significantly smaller than common TFs [e.g., LacI, 360 amino acids; TetR, 207 amino acids (table S1)], making it an ideal scaffold for developing a new set of small or minimal activators or dual TFs (fig. S1B). In addition, a set of Cro activators would complement the λ cl synthetic biology toolbox (12) for gene circuit engineering in bacterial cells (13, 14), because cl and Cro function on related operators.

**RESULTS**

**M13 phagemid-assisted continuous evolution**

To obtain a set of small transcriptional activators derived from λ Cro, we converted our phagemid-based batch selection system (12, 15) for accelerated continuous evolution in a manner similar to phage-assisted continuous evolution (PACE) (16, 17). One difference between our system and classic PACE is that we use phagemids rather than phage to facilitate screening large libraries. The smaller size of the phagemid enables the construction of gene libraries with a much higher number of variants than standard phage. We also prevent bystander mutations in phage genes by placing them on helper plasmids (HP) and accessory plasmids (AP), respectively (Fig. 1A). These plasmids are continuously replenished within fresh uninfected cells (Fig. 1B). The resulting phagemid evolution system, which we call phagemid-assisted continuous evolution (PACEmid), is based on conditional M13 bacteriophage replication. The selection process takes place inside E. coli cells by linking the evolving TF activity to restoring essential phage Gene VI expression (deleted from the HP). In this way, a TF with novel properties can be selected after several cycles of reinfection (Fig. 1B), and the process can be automated (Fig. 1, C and D).

For continuous selection, we found it essential to tune the basal Gene VI expression rate to produce sufficient amounts of phage in the absence of an active TF, reducing the chances of phage loss in the lagoon. We carried out model selections with cIopt [a λ cl optimized mutant with a strong activation region (18)] and showed that selection stringency and rate can be tuned by changing the copy number (19) of the AP (fig. S2). Furthermore, enrichment of cIopt was more efficient in continuous mode than in batch mode under...
the same selection pressure (fig. S3), confirming the advantages of continuous selection (16, 17) for accelerated evolution.

We next implemented a mutagenesis device to expand the mutation spectrum beyond combinatorial libraries. On ColEI-derived plasmids, such as our phagemid, the leading-strand replication pol I is gradually replaced by pol III over at least 1.3 kb downstream of the origin of replication (20). We therefore characterized the efficiency of three mutagenesis cassettes carrying error-prone pol I [EP pol I (21)] or error-prone pol III variants [MP4 and MP6 (22)] under the inducible promoters PBAD and PLlac (23). Mutation rates were then analyzed by a β-lactamase stop codon reversion assay (fig. S4A), a rifampicin resistance assay (fig. S4, B and C), and by monitoring loss of red fluorescent protein (RFP) function on M13 phagemids after three rounds of batch evolution (fig. S4, D and E). The use of the MP6 (22) cassette under the isopropyl β-D-1-thiogalactopyranoside (IPTG)–inducible promoter PLlac (PLlac-MP6-SpecR) led to the highest mutation rates, and this was chosen for downstream applications (fig. S4F). When induced with arabinose, the original MP6 leads to a 322,000-fold increase in mutation rate over that of wild-type (WT) E. coli. This results in an average of 6.2 × 10⁻⁶ substitutions per base pair (bp) per generation (22).

To validate the use of the adapted MP6 (22) mutator cassette for directed evolution, we first evolved an improved orthogonal λ cl TF [cl₄₅₆₇₉₆₇₈; formerly the least active member of our cl toolkit (12)] (fig. S5A). The resulting cl variant had a Met-to-Thr mutation at position 42, leading to an improved dual activation-repression of green fluorescent protein (GFP) and mCherry (fig. S5B). The evolved cl₄₅₆₇₉₆₇₈ led to a 5.4-fold increase in GFP expression and a 91% repression of mCherry (fig. S5, C and D) (full sequences in the Supplementary Materials). In comparison, expression of the parental
ci_{4AST6T,P(M42)} only displayed a 4.3-fold activation and a 58% repression. Notably, position 42 was not randomized in our previously constructed $\lambda$ ci library and, thus, confirmed the potential of extra mutagenesis for improved protein activities.

**Directed evolution of Cro activators**

To see whether the optimized phagemid selection system was powerful enough to select a small Cro activator that could function in *E. coli*, we first constructed a bidirectional promoter (P_{CS}/P_{M,CS}), with three operator sites (O1, O2, O3) (Fig. 2A). O1 and O2 consisted of the $\lambda$ operator consensus sequence (CS), with the highest reported affinity for $\lambda$ Cro (24, 25). As Cro binds with a very high affinity to WT O3 (24), a mutated O3 site was used to reduce potential auto-repression of the P_{M,CS} promoter by $\lambda$ Cro. Basal promoter activity of P_{CS}/P_{M,CS}, as well as the effect of Cro on expression levels, was characterized by GFP and mCherry production and showed that WT Cro repressed in both promoter directions (Fig. 2, B and C).

To search for activators, a combinatorial library of Cro variants was constructed by randomizing four amino acids in $\alpha$ helix two and three (11) (Fig. 2D). Three residues (T17, K21, and D22) were in the potential activation patch, whereas the fourth residue (Y26) was upstream of the $\alpha$ helix necessary for DNA binding. We then constructed an AP with Gene VI under the engineered P_{M,CS} promoter, on the pSC101 vector for high selection stringency. The combinatorial Cro library was selected against this AP for 3 days in continuous culture, leading to a reproducible enrichment of Cro activators in two separate bioreactors (Fig. 2, E and F). The selected activators had at least three amino acid substitutions at the randomized positions over WT Cro (Fig. 3A). Notably, 10 of the 12 selected Cro activators contained an asparagine N at position 26. The importance of N26 for activity was confirmed with site-directed mutagenesis (fig. S6, A and B). The activity of the selected Cro activators (Cro_{Act}) was then analyzed with the reporter assay (Fig. 2A). Cro_{Act} variants up-regulated GFP expression 2.3- to 5.8-fold and repressed mCherry between 52 and 100% (fig. 3, B and C). In comparison, $\lambda$ ci expression resulted in a 6.7-fold activation and a 100% repression of the bidirectional P_{R}P_{RM} promoter (fig. S6, C and D). The most active variants possessed the amino acids V17, A21, E22, and N26 (Cro_{Act1}), and T17, V21, E22, and N26 (Cro_{Act8}) at the randomized positions; both were strong activators and inhibitors of the dual promoter in Fig. 2A.

Next, we explored a wider mutation space using the mutagenesis cassette (P_{Iac}-MP6-SpecR). To achieve this, we applied continuous directed evolution for 4 days, using an optimized pLITMUS* vector backbone (fig. S7, A to C) and starting with the least-active variant Cro_{Act10} (Fig. 3A and fig. S7D). Directed evolution was performed under a medium selection pressure (medium copy number plasmid pJPC12) compared to library selections (low copy pSC101; strong...
selection pressure). This resulted in higher phage production rates and, thus, an increased number of Cro variants. Five additional Cro activators were, thus, evolved with single amino acid changes in the polymerase interaction site (CroAct13 to CroAct16) or DNA binding α-helix (CroAct17) (Fig. 3, D to F). Notably, a new amino acid change at position 31, N31S in the DNA binding α-helix of CroAct17, had a strong impact on the TF activity. To summarize, we obtained a set of 17 small Cro activators with a broad range of activities.

**Gene network engineering based on Cro activators**

To test the potential for gene network engineering with the evolved Cro activators, we selected CroAct3 (5.3-fold activation, 100% repression) for use in combination with our set of orthogonal cI variants (12). Successful combination would allow the construction of a wide range of gene networks that integrate multiple inputs for activation and/or repression, based on variants of commonly used λ promoters. First, we verified the lack of cross-reactivity of the CroAct3 to any of the synthetic promoters of the orthogonal cI toolkit (fig. S8). Having found no unwanted cross-reactivity, we built two different gene circuits. In the first network, gradual addition of arabinose resulted in expression of CroAct3 and, thus, a concentration-dependent increase in GFP and a decrease in mCherry, as expected (Fig. 4, A and B). Note that arabinose addition generally leads to an induction of more cells rather than increased levels of all cells as the PBAD promoter has an all-or-nothing response (26). In the second circuit, expression of the two orthogonal TFs CroAct3 and cl5G6G,P, linked to the inducers arabinose and 3OC6-HSL, resulted in a concentration-dependent increase in the reporters GFP and mCherry, as designed (Fig. 4, C and D). Therefore, CroAct3 can be used for gene circuit engineering, either alone or in combination with other orthogonal TFs, and can target unidirectional as well as bidirectional promoters in a concentration-dependent manner.

**Rational engineering of a minimal 63–amino acid dual TF**

At 66 amino acids, CroAct3 already had a claim to being the smallest activator and dual TF that enables polymerase recruitment. However, we sought to push the boundaries of the smallest possible such TF. By identifying functional breakpoints in the expected structure (Protein Data Bank ID: 6CRO), we made targeted deletions to the C-terminal end of the TF and analyzed the variants using our reporter assay (Fig. 5A). Thus, we found that a minimal 63–amino acid protein (CroAct363aa) is still capable of transcriptional activation or repression in *E. coli* (4.4-fold activation, 88% repression) (Fig. 5, B and C). To our knowledge, this makes it the smallest dual TF that enables polymerase recruitment.

**DISCUSSION**

We chose to evolve λ Cro because of its small size, its biological function as counterpart to λ cI, and its use in numerous synthetic biology projects (27–30). Furthermore, Cro’s α-helix two is positioned to be able to interact with the same part of RNA polymerase that λ cI binds. The evolved Cro activators described in this study can easily

---

**Fig. 3. Analysis of Cro dual TF activator-repressors.** (A) Sequencing results of 12 selected dual Cro activators. WT amino acids are highlighted in orange, and non-WT amino acids in green. (B and C) Activation and repression of the bidirectional promoter Pcs/Pm,cs by the selected Cro variants. GFP and mCherry expression was normalized to OD600. (D) Sequencing results from continuous directed evolution using the mutagenesis plasmid on least-active variant CroAct12. (E and F) Activation and repression of the bidirectional promoter using the variants in (D). All data represent the average of four biological replicates, and error bars correspond to the SD between the measurements.
**Fig. 4. Synthetic gene circuits based on the evolved minimal activator CroAct3.** (A) Design of a one-input gene network on a bidirectional promoter. The arabinose (Ara)–inducible sensor induces CroAct3 operating on a bidirectional promoter and two reporter genes. Operators: O1CS and O2CS sites (orange) recruit CroAct3; O3ob (white) is an obliterated site to circumvent TF binding. (B) Experimental data for the one-input system showing the concentration-dependent response of GFP and mCherry. (C) Design of a two-input gene network on two unidirectional promoters. Two sensors (P_BAD and P_Lux*) act on an integrating circuit with two orthogonal TFs (CroAct3 and cI5G6G,P) operating on two unidirectional promoters and two reporter genes. Operators: O1CS and O2CS sites (orange) recruit CroAct3; O15G6G and O25G6G sites (green) recruit cI5G6GP; O3ob (white) is an obliterated site to circumvent TF binding. (D) Experimental data for the two-input system illustrating the concentration-dependent response of GFP and mCherry to the inducers (Ara, 3OC6). All data represent the average of three biological replicates, and error bars correspond to the SD between the measurements.

**Fig. 5. Engineering of a minimal 63–amino acid dual TF.** (A) Functional breakpoints were identified in the sequence of CroAct3, including a potential structure-breaking Pro59, a positive charge patch ending at Lys63, and a potentially neutral C-terminal Ala66 (bold). The corresponding truncation mutants [59, 63, and 65 amino acids (aa)] were generated; CroAct363aa is shown as an example. Activator mutations to WT λ Cro repressor are highlighted in green. (B and C) Activation and repression of the bidirectional promoter P_CS/P_M,CS by truncated CroAct3 variants. GFP and mCherry expression were normalized to OD600; four biological replicates; error bars represent SD between the measurements. Activation and repression were normalized to the basal expression of each promoter in the absence of any TF on the PM. (D) Model indicating key features of the minimal dual TF, CroAct363aa.
be constructed by site-directed mutagenesis of WT λ Cro, providing a straightforward approach for users to implement these Cro variants into their synthetic biology projects (components are provided in figs. S9 to S11 and tables S2 to S6).

One basic scientific question that we address in this study is whether a small protein repressor can be converted into a transcriptional activator in vivo. Overall, we conclude that not only is this possible but also that even 63 amino acids are sufficient to carry out dual intracellular transcriptional repression and activation by polymerase recruitment (~4.4-fold). It should be noted that TFs are distinct from DNA binding domains (DBDs). For example, certain zinc fingers can form functional DBDs, such as the 63–amino acid domain from GAGA factor [a single zinc-finger unit flanked by two basic rich regions (31)]. However, these interactions are not capable of transcription activation, and the full-length GAGA factor TF is 519 amino acids. A potential alternative to our engineered dual TF is the Arc protein (53 amino acids) from bacteriophage P22, which can act as a repressor or activator (~2.8-fold) (32). However, activation does not occur here by recruiting a polymerase but via accelerating the rate at which the polymerase clears the promoter.

In this study, we used a powerful combination of rational design and directed evolution to obtain a set of Cro activators. An alternative strategy is to simply use directed evolution in the absence of a starting library. This would be very interesting as such an approach would lead to detailed information on specific evolution trajectories. In addition, this might give a time frame on how long it would take to walk through sequence space to obtain these beneficial mutations. Last, it would be interesting to further investigate whether our developed directed evolution platform can be easily transferred to evolve other small repressor peptides.

The small size of TFs raises interesting questions for the de novo evolution of DNA binding and polymerase-recruiting proteins from inert protein scaffolds. Cro belongs to the helix-turn-helix (HTH) superfamily (33), and this study implies that a relatively small amount of secondary structure, including three α helices and three β strands, is sufficient to make a compact scaffold that could support minimal gene activation. As long as there are many ways to reach similar folds, the subsequent number of mutations to make a TF may be more tractable for natural selection [~11 mutations for DNA binding (34) and ~2 to 5 more for transcription activation]. We note that in yeast, a nine–amino acid peptide is sufficient for transactivation (35) and ~2 to 5 more for transcription activation. Overall, this implies that short peptide scaffolds may have a greater capacity to evolve into DNA binding and RNA polymerase-recruiting proteins than previously thought.

MATERIALS AND METHODS

Strains and media
Standard DNA cloning was performed with chemically competent TOP10 cells (Invitrogen) and electrocompetent TG1 cells. Combinatorial library cloning was performed with NEB 5-alpha electrocompetent cells. Phage production was carried out using TOP10, S1030 (36), TG1, or BL21(DE3) cells. All phage-assisted infection assays and reporter assays were performed with TG1 cells. Genotypes of all strains are listed in table S2. Cells were grown in 2× TY medium [NaCl (5 g liter⁻¹), yeast extract (10 g liter⁻¹), tryptone (16 g liter⁻¹)], M9 minimal medium [Na₂HPO₄ (6.8 g liter⁻¹), KH₂PO₄ (3.0 g liter⁻¹), NaCl (0.5 g liter⁻¹), NH₄Cl (1.0 g liter⁻¹), 2 mM MgSO₄, 100 μM CaCl₂, 0.2% (w/v) glucose, 1 mM thiamine-HCl], or Super Optimal broth with Catabolite repression (SOC) medium (Sigma-Aldrich). Chloramphenicol (10 to 25 μg ml⁻¹), kanamycin (25 to 50 μg ml⁻¹), spectinomycin (25 to 50 μg ml⁻¹), ampicillin (50 to 100 μg ml⁻¹), tetracycline (5 to 10 μg ml⁻¹), and carbenicillin (10 μg ml⁻¹) were added where appropriate. IPTG, glucose, or L-arabinose was added to the media to induce or repress the promoter P_Llac (23) or P_RAD.

Cloning and plasmid construction
Subcloning was carried out using Gibson Assembly (37). GFP (GenBank no. KM229386), RFP, and mCherry (UniProt no. X5DSL3) were used as reporters. The λ Cro regulatory protein (UniProt no. P03040) was used as TF scaffold, and the rpoN promoter (P_rpoN) was used to express the evolving gene on the phagemid. The stronger activator cIₗ₃ (18) contains three amino acid changes in the λ cl gene (GenBank no. X00166) at positions 35 to 39 (SVADK to LVAYE). The change in copy number of APs (pSC101, pJPC12, and pJPC13) and the CroAct3,Y26 Variant were obtained by site-directed mutagenesis. All plasmid multiplexes [PSP4 and MP6 (22); EP pol I and WT pol I (21)] were obtained from Addgene and recloned into a vector backbone carrying a spectinomycin resistance gene (SpecR) and a cloDF13 origin of replication to make it compatible with the other plasmids of the directed evolution system. The AraC-P_RAD cassette on MP6-SpecR was replaced with the IPTG-inducible promoter P_Llac (23) (P_Llac-MP6-SpecR). For the construction of gene circuits, a modified version of the P_Lux promoter (P_Lux*) (14) was used to reduce basal expression levels. A degradation tag (AANEDYLYVA) was fused to cl₃G66C at the C-terminal site to decrease basal expression in the absence of an inducer. Promoters, ribosomal binding sites, and terminators were ordered as oligonucleotides (Sigma-Aldrich) or were obtained from previous studies (38, 39). The P_M,C,S promoter contained the mutated O3 sites TATAAATGTGGTGATA (40) or ACAAlCTTCTTGATA to bypass autorepression at high λ cl concentrations. Plasmids were purified using the QIАprep Spin Miniprep Kit or the HiSpeed Plasmid Maxi Kit (QIАGEN). Nucleotide sequences of all cloned constructs were confirmed by DNA sequencing (Eurofins Genomics). The DNA sequences of the synthetic promoters are listed in fig. S9. All plasmids and selected primer sequences are listed in tables S3 to S5. Maps for each class of plasmid are highlighted in fig. S10.

Construction of a combinatorial Cro library
A combinatorial Cro library was cloned on the basis of forward and reverse primers carrying NNS codons (where S = G/C) at positions T17, K21, D22, and Y26, as described previously (table S6) (15). Primers were fused by polymerase chain reaction (PCR), and fragments were cloned into the linearized pLITMUS-P_psp2-Cro-P_Brs 123105¢gIII vector by Gibson Assembly. Cells were transformed and plated on 24-cm² Nunc BioAssay Dishes (Thermo Fisher Scientific). Transformation efficiency was estimated by colony counting of plated serial dilutions. The next day, colonies were harvested and phagemid DNA was purified. Ten clones were sequenced to confirm diversity of the library (table S6). Molecular graphics of TFs were obtained with UCSF Chimera (41).

Selection phage production
Selection phage production was performed in BL21(DE3) cells carrying HP-ΔPS-ΔgIIIAgV1 and pJPC13-ΔPS-ΔT7-gV1 or TOP10 cells containing HP-ΔPS-ΔgIII. Cells were made electrocompetent, phagemids were transformed, and cells were grown overnight at
30°C, 250 rpm (Stuart Shaking Incubator SI500), in 2× TY medium supplemented with kanamycin (12.5 μg ml⁻¹), ampicillin (50 μg ml⁻¹), and chloramphenicol (12.5 μg ml⁻¹) where appropriate. For enrichment assays, plasmids carrying cₐₜ and RFP were mixed in a ratio of 10⁻⁶ before transformation. IPTG (0.25 mM) was added to the BL21(DE3) culture after phagemid transformation to induce Gene VI expression. Samples were centrifuged for 10 min at 8000g, and supernatants were sterile filtered (0.22-μm pore size, Millex-GV). Phage concentration was analyzed by TG1 infection of diluted phage stocks and colony counting on ampicillin plates.

**Phagemid-assisted batch evolution**

TG1 or S1030 cells carrying the helper phage HP·ΔPS·ΔgIII·ΔgVI, a Gene VI–based AP, and, optionally, a mutagenesis plasmid were grown on agar plates (M9 or LB) supplemented with appropriate antibiotics. For TG1-based evolution, starter cultures were inoculated in 2× TY with appropriate antibiotics and grown for 5 to 6 hours at 37°C until the OD₆₀₀ (optical density at 600 nm) reached 0.3 to 0.6. For S1030-based evolution, overnight cultures were inoculated from single colonies. The next day, selection cultures were prepared with a 100-fold dilution of the overnight cultures, and cells were grown for 3 to 4 hours at 37°C until the OD₆₀₀ reached 0.3 to 0.6.

 Cultures were infected at a desired multiplicity of infection (MOI), and a chemical inducer was added where appropriate. Cell cultures were incubated for 20 hours at 30°C, 250 rpm (Stuart Shaking Incubator SI500). Overnight cultures were centrifuged for 10 min at 8000g, and the phage supernatant was used to start a new round of evolution. After each round, phage supernatants were diluted before infecting TG1 cells carrying an appropriate reporter plasmid. Infected cells were selected on ampicillin plates, and single colonies were grown overnight in 2× TY medium supplemented with ampicillin. Phagemid DNA was purified using the QIAprep Spin Miniprep Kit (QIAGEN) and analyzed by sequencing (Eurofins Genomics).

**Phagemid-assisted continuous evolution**

Glass bottles, chemostats, and lagoons connected via biocompatible tubing (Cole-Parmer) were autoclaved and cooled down to room temperature. The autoclaved chemostats and lagoons were placed into two incubators (SID60, Stuart) on individual shakers (Topolino Mobil, IKA). Before each experiment, the bioreactor was equilibrated by pumping 2× TY supplemented with the appropriate antibiotic through the system at 20 ml hour⁻¹ (Pharmacia Biotech Pump P-1).

S1030 cells carrying the modified helper phage HP·ΔPS·ΔgIII·ΔgVI, an AP, and, optionally, a mutagenesis plasmid were grown on agar plates supplemented with appropriate antibiotics and 1% (w/v) d-glucose. The next day, 10-ml cultures were inoculated from single colonies, grown overnight at 37°C, 250 rpm, and stored at 4°C. Starter cultures were inoculated with a 100-fold dilution of the overnight culture and grown at 37°C, 250 rpm, until the OD₆₀₀ reached 0.3 to 0.6. Chemostats were filled with 25 ml of this starter culture, and cells were grown at 37°C with magnetic stir-bar agitation. The lagoon was filled with 40 ml of the starter culture, and cells were infected at a MOI of 4 and 1 mM IPTG was added where appropriate. The infected cells were grown at 30°C with magnetic stir-bar agitation. The flow rate of 2× TY supplemented with the appropriate antibiotics was set to 20 ml hour⁻¹ to provide continuous supply of media. IPTG (10 mM) in sterile water was added to the lagoon at 2 to 3 ml hour⁻¹ to obtain a final concentration of 1 mM for induced mutagenesis (Pharmacia Biotech Pump P-1). Samples were taken from the outflow of the lagoon, centrifuged, and supernatants were stored at 4°C. Samples were serial diluted before infecting TG1 cells with an appropriate reporter plasmid. Phage titers were analyzed by selection on ampicillin plates and colony counting. Single colonies were picked and grown overnight in 2× TY [ampicillin (100 μg ml⁻¹)]. Phagemid DNA was purified using the QIAprep Spin Miniprep Kit (QIAGEN) and analyzed by sequencing (Eurofins Genomics). The DNA sequences of selected TFs are listed in fig. S11. For the cₐₜ/RFP enrichment assay, TG1 cells were infected with phage dilutions and plated on ampicillin plates. The ratio of white to red colonies was analyzed by colony counting, and white colonies were linked to cₐₜ infection by colony PCR.

**β-Lactamase reversion assay**

TG1 cells were transformed with the reporter plasmid pLA230 and (i) cloDF-Pₐ₅BAD-pola-SpecR, (ii) cloDF-Pₐ₅BAD-EpPolA-SpecR, (iii) cloDF-Pₐ₅BAD-MP4-SpecR, or (iv) cloDF-Pₐ₅BAD-MP6-SpecR and streaked out on LB plates supplemented with spectinomycin, kanamycin, and 1% (w/v) d-glucose. The plasmid pLA230 (21) carries a β-lactamase gene with the ochre stop codon TAA at amino acid position 26, which is located 230 bp downstream the origin of replication. The next day, single colonies were picked and grown to the mid-log phase in the presence of 1% d-glucose. Cultures were induced with 1% (w/v) arabinose and incubated for 24 hours at 37°C, 250 rpm (Stuart Shaking Incubator SI500). Cells were diluted and plated on LB plates in the presence or absence of ampicillin and 1% d-glucose and incubated overnight at 37°C. The ratio of the number of ampicillin-resistant colonies divided by the total number of colonies on LB plates was calculated.

**Rifampicin resistance assay**

TG1 cells were transformed with MP4-SpecR or MP6-SpecR and plated on LB plates with the appropriate antibiotics and 1% (w/v) d-glucose. The next day, single colonies were picked and grown to the mid-log phase in the presence of 1% d-glucose. Next, cultures were induced with 1% (w/v) arabinose and incubated for 24 hours at 37°C, 250 rpm. Cells were diluted and plated on LB plates with 1% d-glucose in the presence or absence of rifampicin and incubated in the dark for 24 hours at 37°C. The ratio of the number of rifampicin-resistant colonies divided by the total number of colonies on LB plates was calculated.

**RFP mutation assay**

S1030 cells carrying HP·ΔPS·ΔgIII·ΔgVI, pJPC12·ΔPS·Pₐ₅-lac-SpecR, RBss_Bra_B0034·gVI, and a mutagenesis plasmid (MP4-SpecR, MP6-SpecR, Pₐ₅-lac-MP6-SpecR) were grown in 2× TY medium supplemented with antibiotics and 1% d-glucose until the OD₆₀₀ reached 0.4 to 0.6. Cells were infected with an RFP-carrying phagemid (pLITMUS-Pₐ₅BAD_R0010-RFP-Pₐ₅BAD_J23106-gIII) at MOI 1 and cultured in the presence or absence of an inducer (1% arabinose or 1 mM IPTG) for 20 hours at 30°C, 250 rpm. Phage supernatants were harvested the following day, and experiments were performed for three rounds of evolution in batch mode. TG1 cells were infected with diluted phage supernatants after each round and streaked out on LB plates supplemented with ampicillin. Plates were incubated overnight at 37°C, and the following day, white and red colonies were counted and the ratio was calculated.
Analysis of gene circuits

Single colonies from TG1 cells carrying a pPC12-derived reporter plasmid and a p15A-derived TF plasmid were grown for 3 to 4 hours in 2 ml of 2× TY supplemented with chloramphenicol (5 μg/ml) and carbenicillin (5 μg/ml). The cultures were diluted to OD600 0.01 in a total volume of 150 μl in each well of a 96-well plate. Arabinose (0.01, 0.1, 1, and 2%) and N-(β-ketocaproyl)-l-homoserine lactone (3OC6-HSL; 0.01, 0.1, 1, and 2 μM) were added where appropriate. The absorbance was measured every 10 min in a Tecan Infinite F200 PRO plate reader (37°C, shaking between readings) until the E. coli cells reached stationary phase. For data analysis, fluorescence readings in the late-exponential phase (OD600 of 0.2 for pLITMUS, OD600 of 0.9 for pLITMUS*) were used. Both absorbance and fluorescence were background corrected. The fluorescence was then normalized for the number of cells by dividing by the absorbance. The average of three or four biological replicates and the corresponding SD were calculated for each sample.

SUPPLEMENTARY MATERIALS

Supplemental material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/24/eaba2778/DC1

View/request a protocol for this paper from Bio-protocol.

REFERENCES AND NOTES


**Acknowledgments:** We thank D. B. Holst Hansen for support. **Funding:** This research was supported by the European Commission grant FP7-ICT-2013-10 (no. 610730, EVOPROG) and the EPSRC grant EVO-ENGINE BB/P020615/1. A.J. is funded by FP7-KBBE (no. 613745, PROMYS), H2020 Marie Skłodowska-Curie (no. 642738, MetaRNA), and EPSRC-88SRC (no. BB/M017982/1, WSB center). M.I. is funded by New Investigator award no WT102944 from the Wellcome Trust U.K and by the Volkswagen Foundation. **Author contributions:** Conceived and designed the experiments: A.K.B., A.J., and M.I. Performed the experiments: A.K.B. Analyzed the data: A.K.B. and M.I. Contributed reagents/materials/analysis tools: R.R., A.J., and M.I. Wrote the manuscript: A.K.B. and M.I. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors. A set of plasmids, along with maps and sequences, were deposited in Addgene (IDs are listed in table S3).

Submitted 19 November 2019
Accepted 14 April 2020
Published 10 June 2020
10.1126/sciadv.aba2728

Accelerated evolution of a minimal 63–amino acid dual transcription factor
Andreas K. Brödel, Rui Rodrigues, Alfonso Jaramillo and Mark Isalan

Sci Adv 6 (24), eaba2728.
DOI: 10.1126/sciadv.eaba2728